Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
- Global KRAS Inhibitors Market Opportunity > USD 4 Billion By 2029
- Global KRAS Drug Market Growth In 2022 > 200%
- Number Of Approved Drugs: 2 Drugs
- Approved Drug Global & Regional Sales Insight
- Approved Drugs Patent, Price & Dosage Analysis
- Regional Analysis: USA, UK, China Europe, Japan, South Korea
- Number Of Drugs In Clinical Trials: > 60 Drugs
- Insight On All Drugs In Clinical Trials By Phase, Company, Country, Indication & Patient Segment
Download Report: https://www.kuickresearch.com/report-kras-inhibitor-inhibitors
Cancer tumors employ a number of mutations in the proteins involved in the cell signaling pathways to promote their growth and evasion from the immune system. The KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is the most frequently mutated oncogene, whose variants are expressed in a variety of cancer types. The high expressions of KRAS mutations has brought into the limelight as another target which needs to be considered when developing drugs and therapies for cancer.
Previously, mutated KRAS proteins were largely considered undruggable because of their unusual shapes therefore the development of drugs conforming to the unfamiliar binding grooves was difficult. However, with continuous efforts by researchers and the evolving technologies, it has become possible to now develop drugs against the various KRAS mutations. As of now, Lumakras (Amgen) and Krazati (Mirati) are the only KRAS inhibitors approved for commercial sale. Apart from these, many other candidates are in different phases of development.
Drug regulatory authorities around the world have played in important role in encouraging drug developers to invest more in creating novel KRAS inhibitors through their designation programs which entitle companies and their candidates towards many benefits from the bodies. Recently IBI351/GFH925 developed by Innovent and GenFleet, was granted the breakthrough designation from China’s NMPA as a monotherapy for the treatment of patients with non-small cell lung cancer who have undergone at least one line of previous therapy. Prior to its approval, adagrasib was also granted the breakthrough therapy designation in addition to fast-track and orphan drug designations. All these designations help expedite the drug review and approval processes, enabling them to enter the market sooner than other drugs for their proven improved clinical effects compared to available therapies.
The development of drugs against the KRAS mutations has also fueled another avenue in the cancer researcher domain – the development of diagnostic tests which are capable of identifying KRAS mutations in the samples from patients. Mirati partnered with Qiagen to develop a KRAS companion test to support the former’s Adagrasib. Qiagen’s therascreen KRAS RGQ PCR Kit was recently approved under FDA’s accelerated approval program. Apart from this, three other diagnostic tests have been granted approval by the FDA and in other parts of the world as companion tests for the two approved KRAS inhibitors.
These two factors have largely contributed to a number of collaborations and partnerships. Hookipa and Roche announced a strategic collaboration and license agreement to develop HB-700, Hookipa’s lead candidate for KRAS-mutated cancer. GenFleet became another company to rope in global pharmaceutical giant Merck to conduct clinical trials for its candidate GFH925 in combination with an EGFR inhibitor. Additionally on a different note, Agilent and Quest Diagnostics also announced an agreement to expand the use of ctDx FIRST, a diagnostic test to identify locally advanced or metastatic non-small cell lung cancer (NSCLC) bearing the KRAS G12C mutation.
Certain mergers have been announced too alongside these collaborations. Recently, Elicio Therapeutics and Angion Biomedica announced a definitive merger agreement and stated that the new company will focus on the development of ELI-002, the lead candidate of Elicio, which happens to be a cancer vaccine developed for the treatment of KRAS-mutated tumors. The potential candidate is currently in a phase 1 clinical trial, enrolling patients with pancreatic ductal adenocarcinoma and colorectal cancer as a part of AMPLIFY-201.
KRAS has emerged as one of the most popular targets in cancer therapeutics in recent years for its role in cancer cell growth and expansion. Out of the two approved KRAS inhibitors, Lumakras has already gained market acceptance with more than 200% sales growth in 2022 as compare to 2021 levels, whereas the second drug Krazati was just approved in December 2022. Currently, both drugs have been granted accelerated approval and a full approval will be based on the successful real world data, which is expected to fuel the market, along with data from, ongoing clinical trials.
Contact:
Neeraj Chawla
Kuick Research
Research Head
neeraj@kuickresearch.com
+91-9810410366